Straub, MA
Christopher Straub, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20110015232 | Pyrrolydine Derivatives as IAP Inhibitors - The present invention relates to novel IAP inhibitor compounds of: Formula (I). | 01-20-2011 |
20110065726 | Organic Compounds - The present invention is directed to a compound of the formula: | 03-17-2011 |
20110183955 | 2-Aminocarbonyl Substituted Piperazine or Diaza-Cyclic Compounds as Apoptosis Protein Inhibitors (Iap) Modulators - The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates or pharmaceutically acceptable formulations thereof. These compounds may be used to modulate cellular proliferation and to prevent and/or treat proliferative diseases. | 07-28-2011 |
20110281875 | Inhibitors of IAP - Novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs) of the formula (I). | 11-17-2011 |
Christopher Straub, Stow, MA US
Patent application number | Description | Published |
---|---|---|
20080207630 | 2-Aminocarbonyl Substituted Piperazine or Diaza-Cyclic Compounds as Apoptosis Protein Inhibitors (Iap) Modulators - The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates or pharmaceutically acceptable formulations thereof. These compounds may be used to modulate cellular proliferation and to prevent and/or treat proliferative diseases. | 08-28-2008 |
20080242658 | Inhibitors of Iap - Novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs) of the formula I | 10-02-2008 |
20120207769 | Inhibitors of IAP - Novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs) of the formula (I). | 08-16-2012 |
Christopher S. Straub, Stow, MA US
Patent application number | Description | Published |
---|---|---|
20090069294 | Organic Compounds - The present disclosure relates to XIAP inhibitor compounds of the formula I. | 03-12-2009 |
20110135691 | IMMUNOMODULATION BY IAP INHIBITORS - The present invention is directed to immune adjuvants containing IAP inhibitors, including Smac mimetics. The invention further provides pharmaceutical compositions and vaccines containing an IAP inhibitor and an antigen. Methods of enhancing an immune response by administration of an IAP inhibitor, methods of treating or preventing cancer, methods of treating or preventing infections, methods of treating autoimmune disorders, and methods of potentiating cytokine or antibody production are also provided. | 06-09-2011 |
20110281845 | ORGANIC COMPOUNDS - The present disclosure relates to XIAP inhibitor compounds of the formula I. | 11-17-2011 |
Christopher Sean Straub, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20100048571 | Organic Compounds - The present disclosure relates to XIAP inhibitor compound of the formula I: | 02-25-2010 |
20100249405 | Organic Compounds - The present invention relates to novel IAP inhibitor compounds of formula I: | 09-30-2010 |
20100316573 | Organic Compounds - A method to predict which patients will respond to a IAP inhibiting compound comprising: | 12-16-2010 |
20110206690 | DIMERIC IAP INHIBITORS - The present invention provides compounds of formula M-L-M′ (where M and M′ are each independently a monomeric moiety of Formula (I) and L is a linker). The dimeric compounds have been found to be effective in promoting apoptosis in rapidly dividing cells. | 08-25-2011 |
Christopher Sean Straub, Stow, MA US
Patent application number | Description | Published |
---|---|---|
20090005411 | Combinations of Organic Compounds - The invention provides a pharmaceutical combination comprising: | 01-01-2009 |
20100324083 | Combinations of Organic Compounds - The invention provides a pharmaceutical combination comprising: | 12-23-2010 |
20110319614 | Organic Compounds - The present invention relates to novel IAP inhibitor compounds of formula I: | 12-29-2011 |
20130005663 | SMAC PEPTIDOMETICS USEFUL AS IAP INHIBITORS - The present invention is directed to a compound of the formula: | 01-03-2013 |
20130085153 | COMBINATION OF AN IAP INHIBITOR AND A TAXANE FOR THE TREATMENT OF A PROLIFERATIVE DISEASE - The invention provides a pharmaceutical combination comprising: | 04-04-2013 |
20130217719 | Combination of Organic Compounds - The invention provides a pharmaceutical combination comprising: | 08-22-2013 |
20130266590 | DIMERIC IAP INHIBITORS - The present invention provides compounds of formula M-L-M′ (where M and M′ are each independently a monomeric moiety of Formula (I), (II), (III) or (IV) and L is a linker). The dimeric compounds have been found to be effective in promoting apoptosis in rapidly dividing cells. | 10-10-2013 |
20130309247 | DIMERIC IAP INHIBITORS - The present invention provides compounds of formula M-L-M′ (where M and M′ are each independently a monomeric moiety of Formula (I) and L is a linker). The dimeric compounds have been found to be effective in promoting apoptosis in rapidly dividing cells. (I) | 11-21-2013 |
20140004101 | SMAC PEPTIDOMETICS USEFUL AS IAP INHIBITORS | 01-02-2014 |
Julian Straub, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20150286893 | System And Method For Extracting Dominant Orientations From A Scene - In one embodiment, a method of identifying the dominant orientations of a scene comprises representing a scene as a plurality of directional vectors. The scene may comprise a three-dimensional representation of a scene, and the plurality of directional vectors may comprise a plurality of surface normals. The method further comprises determining, based on the plurality of directional vectors, a plurality of orientations describing the scene. The determined plurality of orientations explains the directionality of the plurality of directional vectors. In certain embodiments, the plurality of orientations may have independent axes of rotation. The plurality of orientations may be determined by representing the plurality of directional vectors as lying on a mathematical representation of a sphere, and inferring the parameters of a statistical model to adapt the plurality of orientations to explain the positioning of the plurality of directional vectors lying on the mathematical representation of the sphere. | 10-08-2015 |
Julie Straub, Winchester, MA US
Patent application number | Description | Published |
---|---|---|
20110129533 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF - Drugs, especially low aqueous solubility drugs, are provided in a porous matrix form, preferably microparticles, which enhances dissolution of the drug in aqueous media. The drug matrices preferably are made using a process that includes (i) dissolving a drug, preferably a drug having low aqueous solubility, in a volatile solvent to form a drug solution, (ii) combining at least one pore forming agent with the drug solution to form an emulsion, suspension, or second solution and hydrophilic or hydrophobic excipients that stabilize the drug and inhibit crystallization, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of drug. Hydrophobic or hydrophilic excipients may be selected to stabilize the drug in crystalline form by inhibiting crystal growth or to stabilize the drug in amorphous form by preventing crystallization. The pore forming agent can be either a volatile liquid that is immiscible with the drug solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. The resulting porous matrix has a faster rate of dissolution following administration to a patient, as compared to non-porous matrix forms of the drug. In a preferred embodiment, microparticles of the porous drug matrix are reconstituted with an aqueous medium and administered parenterally, or processed using standard techniques into tablets or capsules for oral administration. | 06-02-2011 |
Julie Ann Straub, Winchester, MA US
Patent application number | Description | Published |
---|---|---|
20100062066 | Formulations of Tetrahydropyridine Antiplatelet Agents for Parenteral or Oral Administration - A pharmaceutical composition for the oral or parenteral administration of a compound of Formula (I) comprising an oil in water emulsion, wherein the oil phase comprises the free base of or a pharmaceutically acceptable salt thereof of a compound of Formula (I), and one or more surfactants which are soluble in the oil phase and/or the aqueous phase. The emulsion optionally contains one or more excipients that are soluble in the oil phase and/or the aqueous phase, such as pH modifying agents such as buffers, osmolality/tonicity modifying agents, emulsifying agents, water-soluble polymers, and preservatives. The compound of Formula (I) can be formulated as a solid material and stored until needed. Kits for forming the emulsion are provided. Prior to administration, the solid material can be reconstituted in an aqueous medium to form the emulsion. | 03-11-2010 |
Michelle Marie Straub, Brighton, MA US
Patent application number | Description | Published |
---|---|---|
20150337034 | COMPOSITIONS AND METHODS FOR GROWTH FACTOR MODULATION - Provided herein are proteins, antibodies, assays and methods useful for modulating growth factor levels and/or activities. In some embodiments, such growth factors are members of the TGF-β superfamily of proteins. | 11-26-2015 |